Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) EPS (Basic) (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed EPS (Basic) for 9 consecutive years, with -$0.05 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Basic) rose 54.55% to -$0.05 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.02, a 93.94% increase, with the full-year FY2025 number at -$0.02, up 93.94% from a year prior.
  • EPS (Basic) was -$0.05 for Q4 2025 at Akebia Therapeutics, down from $0.0 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.16 in Q2 2022 to a low of -$0.51 in Q2 2021.
  • A 5-year average of -$0.14 and a median of -$0.08 in 2023 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): crashed 3458.5% in 2024, then surged 133.33% in 2025.
  • Akebia Therapeutics' EPS (Basic) stood at -$0.4 in 2021, then skyrocketed by 90.0% to -$0.04 in 2022, then skyrocketed by 108.19% to $0.0 in 2023, then tumbled by 3458.5% to -$0.11 in 2024, then soared by 54.55% to -$0.05 in 2025.
  • Per Business Quant, the three most recent readings for AKBA's EPS (Basic) are -$0.05 (Q4 2025), $0.0 (Q3 2025), and $0.0 (Q2 2025).